TTrialPathMatch Me to Trials
← Back to trials
RecruitingRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRefractory B Acute Lymphoblastic Leukemia

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This phase I trial tests the safety and effectiveness of pomalidomide after CD19 chimeric antigen receptor T-cell (CD19CART) therapy for the treatment of patients with CD19+ B-cell leukemias or lymphomas that have come back after a period of improvement (relapsed) or do not respond to treatment (refractory). Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T-cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells and are then re-infused into the patient. Following CAR T-cell infusion, CAR T-cells must expand and persist in the blood stream in order to most effectively treat leukemia/lymphoma. Pomalidomide stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells. Research has shown that drugs like pomalidomide can modify the immune system and increase the number or improve the function of CAR T-cells in the blood. Pomalidomide may enhance the treatment effects of CAR T-cell therapy in patients who have received CD19CART therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma.

Sponsor: University of Michigan Rogel Cancer Center

You may qualify if…

  • ✓ Subject must have had a histologically or cytologically confirmed R/R CD19+ B-cell leukemia or lymphoma and have received a commercially available CAR-T product approved to treat R/R CD19+ Bcell leukemias and lymphomas.
  • ✓ Subject must be 28 - 56 days post infusion of CD19CART product at time of enrollment.
  • ✓ \>= 18 years in age at time of enrollment
  • ✓ Subject is able to swallow pills/tablets
  • ✓ Karnofsky performance score of \>= 50%
  • ✓ Absolute neutrophil count (ANC) \>= 750/mm\^3 (granulocyte colony stimulating factor allowed)
  • ✓ Platelets \>= 50,000/mm\^3 (transfusion independent for \>= 7 days, defined as not receiving platelet transfusions for at least 7 days prior to enrollment, unless due to marrow involvement from primary malignancy \[thrombopoietin (TPO) mimetics allowed\])
  • ✓ Total bilirubin =\< 1.5 x upper limit of normal (ULN) per institution

You may not qualify if…

  • ✕ Patients with known progressive or refractory disease.
  • ✕ The following transplant or CAR T-related events are excluded:
  • ✕ Active grade \>= 2 acute or chronic graft versus host disease (GVHD)
  • ✕ Active cytokine release syndrome (CRS) grade \>= 2
  • ✕ Active immune effector cell associated neurotoxicity (ICANS) grade \>= 2
  • ✕ Subject receiving \>= 0.25 mg/kg/day of methylprednisolone equivalent. Subject being treated with medications with a known major drug interaction to pomalidomide. Specifically, patients receiving CYP1A2 inhibitors, such as ciprofloxacin, omeprazole, cimetidine, estrogen, and fluvoxamine.
  • ✕ Patient who smokes cigarettes.
  • ✕ Subject must not have initiated or received intervening therapy for a primary or secondary malignancy within 28 days of study enrollment, including, a) myelosuppressive chemotherapy, b) biologic anti-neoplastic agents (e.g., ruxolitinib, imatinib, dasatinib…), or checkpoint inhibitors (e.g., pembrolizumab). The use of cytokine inhibition for management of CRS/ICANS is allowed within the prior 28 days

Where it's recruiting

Michigan

Ann Arbor

Source: ClinicalTrials.gov · NCT07532525 · last updated 2026-10-15

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or · TrialPath